First Patient Dosed in Phase II Clinical Trial for BioInvent's Cardiovascular Drug, BI-204

Trial start triggers US$ 15 million milestone from Genentech

16-Mar-2011 - Sweden

BioInvent International AB  announced the dosing of the first patient in the phase II study of the Company’s antibody, BI-204. The product candidate is being developed for secondary prevention of cardiovascular events in patients with Acute Coronary Syndrome.

The Phase II study is a multicenter, randomized, double-blind, placebo-controlled study of BI-204, delivered intravenously to patients on standard-of-care therapy for stable atherosclerotic cardiovascular disease. The trial will enrol 120 patients at approximately 20 centres in the United States and Canada. It is designed to demonstrate a reduction in plaque inflammation following treatment as quantified by FDG-PET imaging (18F 2‑deoxyglucose positron emission tomography).

The antibody is being developed in collaboration with Genentech, a member of the Roche Group. BioInvent will receive a milestone payment of US$ 15 million from Genentech upon dosing of the first patient.

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous